What development phase is Cofrel in?

Cofrel is FDA-approved (marketed).

What is the generic name of Cofrel?

BENPROPERINE is the generic (nonproprietary) name of Cofrel.

Last reviewed 2026-04-20 · How we verify

Cofrel (BENPROPERINE)

FDA-approved active Small molecule Quality 13/100

BENPROPERINE (Cofrel) is a marketed cough medication with a key composition patent expiring in 2028. Its key strength lies in its specific molecular target interaction, which differentiates it from off-patent competitors like benzonatate, pentoxyverine, and clofedanol. The primary risk is the potential increase in competition from generics once the patent expires in 2028.

At a glance

Generic name	BENPROPERINE
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

Cough

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cofrel CI brief — competitive landscape report
Cofrel updates RSS · CI watch RSS